In nonobese diabetic (NOD) mice, type I diabetes can be prevented without generalized immunosuppression by nonhypercalcemic analogs of vitamin D 3 when treatment is started early, i.e. before the autoimmune attack, reflected by insulitis, occurs. The aim of this study was to investigate whether these substances can arrest progression to clinically overt diabetes when administered in a more advanced disease stage, namely when the autoimmune attack is ongoing, reflecting the situation in prediabetic subjects in whom immune intervention is being considered. We, therefore, evaluated the protective potential of MC1288 (20-epi-1,25-dihydroxyvitamin D 3 ) a nonhypercalcemic analog of 1,25-dihydroxyvitamin D 3 , both alone and in combination with a short induction course of cyclosporin A, in NOD mice that already have insulitis, as demonstrated in pancreatic biopsies performed 15 days before the start of therapy. Subsequently, mice were randomized into a control group, receiving the treatment vehicle (n ϭ 26), and three treatment groups, receiving, respectively, 7.5 mg/kg⅐day cyclosporin A (CyA) from days 85-105 (n ϭ 19), 0.1 g/kg⅐2 days MC1288 from days 85-200 (n ϭ 20), or the combination of these two regimens (n ϭ 20). At the time of the pancreatic biopsy (day 70), insulitis was evenly distributed in all groups, and 27.7% of the islets scored showed signs of destructive insulitis. Diabetes outcome by 200 days was 74% (14 of 19) in the CyA-treated group, comparable to the diabetes incidence in control mice (65%; 17 of 26; P ϭ NS). Treatment with MC1288 alone could not reduce disease incidence (70%; 14 of 20), but the combination therapy reduced diabetes incidence to 35% (7 of 20; P Ͻ 0.05 vs. untreated; P Ͻ 0.01 vs. CyA group; P Ͻ 0.025 vs. MC1288). All treatments were well tolerated, without major side-effects on calcium or bone metabolism and without signs of generalized immunosuppression. Cotransfer experiments could not reveal the induction of suppressor cells. Reverse transcription-PCR on pancreatic tissue revealed significantly lower levels of interferon-␥ and higher levels of interleukin-4 in the combination group. In conclusion, nonhypercalcemic analogs of 1,25-dihydroxyvitamin D 3 administered to NOD mice when the autoimmune disease is already active can prevent clinical diabetes when this therapy is combined with a short induction course of an immunosuppressant such as CyA. (Endocrinology 139: [95][96][97][98][99][100][101][102] 1998) T YPE I diabetes, insulin-dependent diabetes mellitus, results from a specific destruction of the pancreatic islet ␤-cells by the immune system (1). The precise etiology and pathogenesis of type I diabetes remain unclear, but studies in humans and the animal models, especially the nonobese diabetic (NOD) mouse, have demonstrated that a genetic background and an immune imbalance are determining factors (2-4). Abnormalities of the immune system described in humans and in the NOD mouse include a maturation defect in the monocytic lineage in the bone marrow and defects in antigen presentation and in the generation of suppressor cells (5-7). Several intervention strategies have been tested in the NOD mouse to develop models for the prevention of human autoimmune diabetes. Disease prevention in the NOD mouse can be achieved by chronic use of immunosuppressants such as cyclosporin A (CyA) (8), but such an approach is not desirable in humans because of the side-effects.
T YPE I diabetes, insulin-dependent diabetes mellitus, results from a specific destruction of the pancreatic islet ␤-cells by the immune system (1) . The precise etiology and pathogenesis of type I diabetes remain unclear, but studies in humans and the animal models, especially the nonobese diabetic (NOD) mouse, have demonstrated that a genetic background and an immune imbalance are determining factors (2) (3) (4) . Abnormalities of the immune system described in humans and in the NOD mouse include a maturation defect in the monocytic lineage in the bone marrow and defects in antigen presentation and in the generation of suppressor cells (5) (6) (7) . Several intervention strategies have been tested in the NOD mouse to develop models for the prevention of human autoimmune diabetes. Disease prevention in the NOD mouse can be achieved by chronic use of immunosuppressants such as cyclosporin A (CyA) (8) , but such an approach is not desirable in humans because of the side-effects.
A more specific immunomodulation aiming at restoring the immune imbalance without interfering with the overall immune defense systems is clinically more attractive (9 -11) . We have demonstrated that the active form of vitamin D, 1,25-dihydroxyvitamin D 3 [1, 2 D 3 ] and its nonhypercalcemic analogs, exert such immunomodulation and can prevent insulitis and diabetes in the NOD mouse (12) (13) (14) . Indeed, 1,25-(OH) 2 D 3 and its analogs did not induce a generalized immunosuppression, but provoked after long term treatment a restoration of the defective regulator system in the NOD mouse. The actions of this family of molecules on the immune system are exerted via receptors for 1,25-(OH) 2 D 3 that are present in several immune cells, such as monocytes/macrophages, activated T lymphocytes, and B lymphocytes. 1,25-(OH) 2 D 3 and some of its analogs induce differentiation of monocytes toward macrophages and stimulate their activity (15) (16) (17) . On the other hand, these substances inhibit T cell proliferation and cytokine production, such as interleukin-2 (IL-2), IL-12, and interferon-␥ (IFN␥) (18 -21) . These in vitro effects are reflected in vivo by a protection against many autoimmune diseases and a prolongation of allograft survival (12) (13) (14) (22) (23) (24) (25) (26) .
In the NOD mouse, insulitis and diabetes incidence was lowered by 1,25-(OH) 2 D 3 and its nonhypercalcemic analogs when treatment was started before the appearance of insulitis and, thus, the initiation of autoimmunity (12) (13) (14) . The first group of subjects in whom active diabetes prevention would be applied, however, consists of prediabetic relatives of type I diabetic patients in whom the autoimmune attack is already ongoing. Therefore, before introducing the analogs of 1,25-(OH) 2 D 3 for the treatment of such subjects, it has to be clarified whether these analogs can also arrest the progression to clinically overt diabetes. The aim of this study was to evaluate the therapeutic potential of one of these analogs, MC1288 [20-epi-1,25-(OH) 2 D 3 ], both alone and in combination with a short induction course of CyA, in a model of spontaneous diabetes, the NOD mouse, when started after the autoimmune attack against the ␤-cell, as reflected by the presence of insulitis. To prove the presence of this ␤-cell attack before any treatment was started, pancreatic biopsies to demonstrate the presence of insulitis beyond any doubt were performed in each individual mouse. By themselves, these biopsies did not alter the incidence of diabetes in the controls and allowed for histological certainty about ongoing autoimmunity in treated mice.
Materials and Methods Animals
NOD mice that were originally obtained from Prof. Wu in 1990 (Beijing, China) were bred in our animal house and kept under conventional conditions (27) . They were fed a low calcium, vitamin D-replete diet (0.2% calcium, 1% phosphate, and 2000 U vitamin D/kg; Hope Farms, Woerden, The Netherlands). Diabetes incidence by the age of 200 days in stock mice at the time of the study was 79% in female and 23% in male mice. In this study only female NOD mice were used. After the age of 200 days, the further increase in diabetes incidence in the colony was less than 1%.
Experimental design and treatment regimen
Pancreatic biopsies were performed in female NOD mice at the age of 70 days to histologically confirm the presence of insulitis in each individual mouse. Biopsies were taken by resecting a small piece (3 mm 3 ) of the pancreas of ether-anesthetized mice. Each procedure was performed under sterile conditions, with a mortality rate of 1%. Pancreas biopsies were fixed in Bouin's solution and embedded in paraffin. Serial sections were made and stained with hematoxylin and eosin. Biopsies were scored for insulitis in a double blinded manner, and at least seven different islets per biopsy were examined. The level of lymphocytic infiltration in the islets was scored as follows: 0 ϭ no lymphocytes in or around the islets; 1 ϭ periductular infiltrate; 2 ϭ periislet infiltrate; 3 ϭ intraislet infiltrate; and 4 ϭ intraislet infiltrate associated with clear ␤-cell destruction. The mean score for each pancreas was calculated by dividing the total score by the numbers of islets scored. After the surgical procedure, mice were rested for 15 days, and subsequently, independent of the histological score, they were randomized into a control group (n ϭ 26) receiving the treatment vehicle only and three treatment groups receiving, respectively, CyA (7.5 mg/kg⅐day) from days 85-105 (n ϭ 19), MC1288 (0.1 g/kg⅐2 days) from days 85-200 (n ϭ 20), or the combination of these two regimens (n ϭ 20).
CyA was purchased from the Sandoz Co. (Basel, Switzerland), and MC1288 was a gift from Dr. L. Binderup (Leo Pharmaceuticals, Ballerup, Denmark). All drugs were suspended in arachis oil and administered ip. Mice undergoing only the surgical procedure did not show any deterioration in glucose tolerance or any increase in diabetes incidence compared with stock mice.
Evaluation of insulitis and diabetes
Diabetes was evaluated as described previously (12) . Briefly, mice were weighed weekly, and glucosuria was tested 3 times a week starting at the age of 30 days using Clinistix (Bayer Diagnostics, Basingstoke, UK). Glycemia was determined with a Glucocard (Menarini, Firenze, Italy). Mice were considered diabetic when they had glucosuria and a glycemia exceeding 230 mg/dl (13 mm) on 2 consecutive days. Mice becoming diabetic before the age of 85 days were excluded from the study. At diabetes diagnosis or at 200 days of age, mice were killed by ether inhalation and cervical dislocation. Pancreases were removed and fixed in Bouin's solution. Hematoxylin-and eosin-stained serial sections were evaluated for insulitis by 2 independent investigators. A mean of 30 islets/pancreas were screened for insulitis. The level of lymphocytic infiltration in the islets was scored as described above.
Parameters of calcium and bone metabolism
Serum concentrations of calcium and osteocalcin, and bone calcium content. At the age of 200 days or at diabetes diagnosis, blood was taken by heart puncture. Total serum calcium was determined by microcolorimetric assay (Sigma Chemical Co., St. Louis, MO), and serum osteocalcin was determined by an in-house RIA that used mouse osteocalcin as standard and a polyclonal guinea pig antimouse osteocalcin antiserum (14) . The within-and between-assay coefficients of variation were 4 and 6%, respectively, and the sensitivity was 0.02 nmol/liter. The calcium content in tibia was measured as described previously (14, 28) .
Calcium and collagen cross-links in urine.
At the age of 180 days, normoglycemic mice (n ϭ 5-10) from each treatment group and control mice were housed for 24 h in metabolic cages, and urine was collected in 10-ml glass tubes containing 10 l 6 n HCl. Calcium in urine was determined using the same microcolorimetric assay as that used for the determination of serum calcium. Collagen cross-links in urine reflect collagen breakdown and bone turnover and were determined as described previously (14, 29) .
In vitro immune evaluation
At the end of the study, normoglycemic mice (n ϭ 5) from each treatment group and the control group were screened for signs of generalized immunosuppression. Moreover, mononuclear cell subsets in the spleen were analyzed by FACS analysis.
T cell suppression was evaluated by performing mixed lymphocyte reactions (MLR) and concanavalin A (Con A) proliferation tests. For MLR, spleens were removed aseptically, gently teased apart, and pressed through a steel mesh. After T cell enrichment by nylon wool passage, splenocytes of test animals (5 ϫ 10 6 /ml; 5 ϫ 10 5 cells/well) were cocultured for 5 days with irradiated (30 Gy; 60 Co source) splenocytes from C57Bl/6 mice as stimulators (5 ϫ 10 6 /ml; 5 ϫ 10 5 cells/well) in RPMI 1640 medium (Life Technologies, Paisley, UK) supplemented with 10% FCS, 100 U/ml penicillin, 100 g/ml streptomycin, and 0.2% mercaptoethanol. Cells were cultured in triplicate in flat bottomed 96-well microtiter tissue culture plates (Nunc, Roskilde, Denmark). Cells were pulsed after 4 days with 1 Ci [methyl-
3 H]thymidine (Radiochemical Center Amersham, Aylesbury, UK), harvested 18 h later on glass filter paper, and counted. Proliferation values were expressed as counts per min.
For Con A stimulation, splenocytes (1 ϫ 10 6 /ml; 2 ϫ 10 5 cells/well) from test mice were cultured in RPMI 1640 added with 10% FCS, 100 U/ml penicillin, 100 g/ml streptomycin, and 0.2% mercaptoethanol in triplicate in flat bottomed 96-well microtiter tissue culture plates (Nunc, Roskilde, Denmark) in the presence of Con A (6.25 g/ml) for 72 h. [Methyl-
3 H]thymidine incorporation was measured after 18 h. Again values were expressed as counts per min.
For the FACS analysis, splenocytes (1 ϫ 10 6 /ml) were incubated for 30 min at 4 C with 10 l fluorescein isothiocyanate-or phycoerythrinconjugated monoclonal antibodies. The markers used were Thy1.2 (pan T cell), L3T4 (CD4), Lyt2 (CD8; Caltag, San Francisco, CA), IgMϩIgG (B cell; Jackson ImmunoResearch Laboratories, West Grove, PA), CD11b (monocytes and macrophages), and ASGM-1 (natural killer cells; Wako Chemicals, Neuss, Germany).
Cotransfer experiments
To detect the existence of suppressor cells, cotransfer experiments were performed. Naive 6-to 8-week-old male NOD mice, were irradiated (7.5 Gy) and received 48 h later 20 ϫ 10 6 splenocytes, iv, which were obtained from overtly diabetic NOD mice (30) . Twenty-four hours before the transfer of the diabetogenic cells, 20 ϫ 10 6 splenocytes from mice treated with MC1288, CyA, or the combination therapy or control mice were injected iv. Mice were tested for glucosuria twice weekly and were considered diabetic following the above-described criteria.
Cytokine analysis by quantitative RT-PCR
Total RNA was extracted from fresh pancreatic tissue (free of lymph nodes), which was taken from normoglycemic test mice from each group (n ϭ 5) at the end of the study, using the acid guanidinium thiocyanatephenol-chloroform method (31) .
A constant amount of 4 g target RNA was reverse transcribed with Superscript II RT (Life Technologies, Merelbeke, Belgium) at 42 C for 80 min in the presence of random primers.
For IL-2, IL-4, IL-10, IL-12, IFN␥, and ␤-actin, real time quantitative PCR was performed (32, 33) . PCR reactions were performed in the ABI Prism 7700 sequence detector, which contains a Gene-Amp PCR System 9600 (Perkin Elmer, Nieuwerkerk a/d Ijssel, The Netherlands). Reaction conditions were programed on a Power Macintosh 7200 (Apple Computer, Cupertino, CA), linked directly to the 7700 Sequence Detector. The assay uses the 5Ј-nuclease activity of Taq polymerase to cleave a nonextendible hybridization probe during the extension phase of PCR. The approach uses dual labeled fluorogenic hybridization probes. One fluorescent dye serves as a reporter (FAM or TET), and its emission spectra is quenched by the second fluorescent dye, TAMRA. The nuclease degradation of the hybridization probe releases the quenching of the FAM fluorescent emission, resulting in an increase in peak fluorescent emission at 518 nm. The use of a sequence detector (ABI Prism) allows measurement of fluorescent spectra of all 96 wells of the thermal cycler continuously during PCR amplification. Therefore, the reactions are monitored in real time. The model 7700 software constructs amplification plots from the extension phase fluorescent emission data collected during the PCR amplification. C T (threshold) values are calculated by determining the point at which the fluorescence exceeds a threshold limit (usually 10 times the sd of the baseline). Primers were chosen with the assistance of the computer program Primer Express (Perkin-Elmer, Norwalk, CT) and were always located in two different exons (Table 1) Table 1 ). For the generation of standard curves, plasmid clones containing a partial cDNA sequence of IL-2, IL-4, and IL-10 were constructed. Briefly, total RNA was extracted from spleens, and cytokine cDNA fragments were generated by RT-PCR using the PCR primers as described above. The amplicons were cloned into pGEM-TEasy (Promega, Leiden, The Netherlands). The length of the amplicons was confirmed by restriction analysis. Serial dilutions from the resulting plasmid clones were used as standard curves, each containing a known amount of template copy number (34) . For the standard curves of the other cytokines and ␤-actin, serial dilutions of a known amount of a cDNA sample were used. The C T values of each cytokine were plotted on these standard curves to obtain the amount of copies present in the initial cDNA sample. Each PCR amplification was performed in quadruplicate, using the following conditions: 2 min at 50 C and 10 min at 95 C, followed by a total of 40 two-temperature cycles (15 sec at 95 C and 1 min at 60 C). A normalization to ␤-actin (housekeeping gene) was performed for each sample. Gel electrophoresis was performed to confirm the correct size of the amplicons and the absence of nonspecific bands.
The relative expression of tumor necrosis factor-␣ (TNF␣) was assessed by a competitive RT-PCR method, described by N. Zhou et al. (35) . Briefly, serial dilutions of an internal RNA standard, designed to be identical to the target messenger RNA (mRNA) except for the addition of an internal 92-bp fragment, were reverse transcribed together with the target RNA. After PCR amplification, the ratio of amplified target to competitor PCR product was determined for each sample. Values were expressed in picograms per g total RNA.
Statistical analysis
Data were expressed as the mean Ϯsd except for histological scoring of insulitis and the PCR results (mean Ϯ sem). Statistical tests used were the 2 test for insulitis and diabetes incidence and cotransfer experiments, the Mann-Whitney U test for immune and cytokine analysis, or Student's t test for histological scoring of insulitis, calcium, and bone parameters. Significance was defined at the 0.05 level.
Results

Incidence of insulitis and diabetes
At the time of the pancreatic biopsy, before any treatment was administered (day 70), insulitis was found to be present in 73%, 79%, 83%, and 71% of the mice to which, respectively, the vehicle treatment, CyA, MC1288, and the combination therapy were subsequently administered (P ϭ NS). The severity of insulitis was comparable in all groups, as demonstrated by mean insulitis scores (1.2 Ϯ 1.1, 1.1 Ϯ 0.7, 1.5 Ϯ 0.9, and 1.2 Ϯ 0.9 in the control group, the CyA group, the MC1288 group, and the combination group, respectively). When classifying the islets according to their insulitis score, a mean of 27 Ϯ 7% of the islets scored showed signs of destructive insulitis (grades 3 and 4), and no differences were seen in the distribution of insulitis scores in the various groups (data not shown). Pancreatic biopsies by themselves did not significantly alter the incidence of diabetes in control NOD mice compared to that in the stock colony [65% (17 of 26) diabetes incidence in sham-operated and vehicle-treated mice vs. 79% (30 of 38) in the stock colony; P ϭ NS]. In the CyA-treated group, the incidence of clinical diabetes by 200 days of age was 74% (14 of 19), which is comparable to the diabetes incidence in vehicle-treated control mice (65%; 17 of 26; P ϭ NS). Treatment with MC1288 alone did not significantly influence diabetes incidence (14 of 20; 70%), but the combination therapy reduced the incidence of diabetes to 35% (7 of 20; P Ͻ 0.05 vs. control; P Ͻ 0.01 vs. CyA group; P Ͻ 0.025 vs. MC1288 group; Fig. 1 ). When comparing the different treatment groups and limiting the analysis to animals presenting with insulitis before treatment was started, the occurrence of diabetes by 200 days of age was 87% (13 of 15) in the group treated with CyA, 69% (11 of 16) in the group treated with MC1288, and 47% (7 of 15) in the group receiving MC1288 and CyA (P Ͻ 0.01 vs. CyA; Fig. 2 ). Considering only animals that were insulitis free at the time of biopsy (day 70), insulitis developed in almost all cases treated with CyA or MC1288 monotherapy (3 of 4 and 4 of 4, respectively). In contrast, only 2 of 5 animals (40%) treated with the combination therapy developed insulitis (P Ͻ 0.05). Interestingly, none of these latter 2 mice progressed to clinically overt diabetes. When analyzing the severity of islet infiltration at the end of the study, control animals had a mean insulitis score of 3.2 Ϯ 1.3, comparable to that of CyAtreated (3.6 Ϯ 0.8; P ϭ NS) and MC1288-treated mice (3.2 Ϯ 1.2; P ϭ NS), but mice treated with the combination therapy had a significantly lower mean score of 2.1 Ϯ 1.5 (P Ͻ 0.05 vs. all other groups). Again when comparing the individual treatment groups and when classifying the islets according to insulitis score, we noted that the group treated with the combination therapy had significantly higher levels of islets with a score of 0 (P Ͻ 0.05) and significantly lower levels of islets with a score of 4 (P Ͻ 0.001). We also noted a trend toward higher numbers of score 2 islets (periinsulitis) in this combination treatment group (Fig. 3) .
Effects on bone and calcium metabolism
Serum concentrations of calcium and osteocalcin, and bone calcium content. Total serum calcium levels, measured 24 h after the last injection, were slightly elevated in analog-treated groups, but remained beneath the toxic range (Table 2) . Osteocalcin levels, indicative of osteoblast activity and bone turnover, were normal in mice treated with CyA or MC1288, but surprisingly they were significantly lower in the combination therapy group (62.8 Ϯ 5.9 vs. 82.8 Ϯ 4.0 g/liter in controls; P Ͻ 0.001; Table 2 ). Bone calcium content was significantly lower in CyA-treated mice, indicating bone decalcification (5.63 Ϯ 0.49 vs. 6.6 Ϯ 0.26 mg/tibia in controls; P Ͻ 0.01), whereas treatment with MC1288 only had no effect on bone calcium (6.43 Ϯ 0.35 mg/tibia; P ϭ NS vs. controls).
Reflecting the low osteocalcin levels and decreased bone turnover, mice treated with the combination therapy presented with a higher calcium content in their tibiae (7.18 Ϯ 0.26 mg/tibia; P Ͻ 0.05 vs. controls).
Urinary calcium excretion and urinary collagen cross-links.
No significant increase in calciuria was observed in mice treated with MC1288, CyA, or the combination therapy ( Table 2 ). The urinary excretion of collagen cross-links (pyridinoline and deoxypyridinoline) was measured to evaluate the effect of the treatment regimens on bone resorption (Table 2) . Treatment with MC1288 increased the excretion of pyridinoline significantly from 592 Ϯ 74 nm/mm creatinine in control mice to 876 Ϯ 76 (P Ͻ 0.001), whereas in NOD mice treated with CyA or the combination therapy the values did not differ significantly from those in controls. The excretion of deoxypyridinoline was comparable in all mice.
Immune evaluation
To evaluate whether the treatment regimens (CyA, MC1288, and the combination therapy) resulted in generalized immunosuppression, MLR-and Con A-induced proliferation tests were performed at 200 days. Lymphocytes taken from 200-day-old NOD mice treated with MC1288, CyA, or the combination therapy proliferated to the same extent as controls, suggesting that no long term generalized immunosuppression was present (Fig. 4) . FACS analysis and phenotyping of T and B lymphocytes, monocytes/macrophages, and natural killer cells in the spleen were performed as well. No significant differences were present among the different treatment groups (Table 3) .
Cotransfer experiments
The presence of suppressor cells was investigated as described above. Sixty percent of young irradiated NOD mice receiving only splenocytes from overtly diabetic NOD mice developed diabetes after 45 days. When a cotransfer was performed using splenocytes from normoglycemic animals treated with MC1288, CyA, or MC1288 and CyA, no protection against diabetes was seen (100% diabetes after 45 days), suggesting that suppressor cells were not induced by any of the treatment regimens.
Cytokine analysis by quantitative RT-PCR
To gain more insight into the protective mechanism of MC1288 and CyA, the cytokine mRNA levels in the pancreases of protected NOD mice were examined. We did not include acutely diabetic mice, as this would bias our results; more diabetic mice were present in the control group and in the groups treated with monotherapy, and these have a more destructive cytokine pattern (data not shown) (36). Even when considering only normoglycemic animals, IFN␥ mRNA levels in pancreases of mice treated with the combination therapy were significantly lower than those in pancreases of control mice (P Ͻ 0.05) and mice treated with CyA alone (P Ͻ 0.05; Fig. 5 ). IFN␥ is the main cytokine whose gene expression is found to correlate with islet ␤-cell destructive insulitis (36). mRNA levels of IL-4 were clearly higher in mice treated with the combination therapy, and this increase was significant compared with those in the CyA group (P Ͻ 0.05; Total serum calcium, osteocalcin, bone calcium content, calciuria, and collagen cross-links were determined as described in Materials and Methods. Note that the combination therapy resulted in a lowering of bone turnover and a higher calcium content. No significant increase in calciuria was observed in mice treated with MC1288, CyA, or the combination therapy. Treatment with MC1288 increased the excretion of PYD significantly (P Ͻ 0.001), whereas in NOD mice treated with CyA or the combination therapy, the values did not differ significantly from those in control mice. The excretion of DPD was similar in all mice.
a P ϭ NS vs. control. 5 ). IL-4 mRNA expression is reported to be more associated with nondestructive insulitis than with ␤-cell destructive insulitis and may act as a diabetes-protective cytokine (34) . In contrast, mRNA levels of IL-10, IL-12, and TNF␣ were not significantly different among any of the treatment groups (Fig. 6 ). IL-2 mRNA levels were very low in all groups (data not shown).
Discussion
1,25-(OH) 2 D 3 and its analogs have been shown to prevent diabetes in the NOD mouse if administered before the autoimmune attack against the ␤-cells has started (before insulitis is present) (12) (13) (14) . The mechanism of this protective action is still unclear, but does not involve a general suppression of T cells. As we previously demonstrated, a restoration of suppressor cell function may be involved (12, 14) .
In this study, we have tested the potential of MC1288 [20-epi-1,25-(OH) 2 D 3 ], alone or in combination with a short induction course of CyA, to arrest the progression from the histological autoimmune attack to clinically overt diabetes in NOD mice when therapy was started after the autoimmune attack had begun. The presence of an active autoimmune attack was evidenced by the presence of insulitis in pancreatic biopsies taken before treatment was started. Treatment with the combination of MC1288 and CyA decreased diabetes incidence with 46% vs. control animals. A critical analysis of these data demonstrates that in mice presenting with insulitis at the time of starting therapy, i.e. the equivalent of prediabetic subjects, MC1288 in combination with CyA (38) . The mechanism of protection in our model is clearly not generalized immune suppression, and cotransfer experiments with splenocytes from animals treated with CyA, MC1288, or the combination therapy did not reveal the presence of suppressor cells. This is in contrast to the findings in NOD mice that had been treated with 1,25-(OH) 2 D 3 or its analogs alone from an early age (21 days) onward (12, 14) . Recent data, however, suggest that also in this long term model the suppressor cells, although they are induced, are not the main mechanism in the protection against diabetes (39) . Therefore, suppressor cells are unlikely to be the only explanation for the protection against diabetes achieved in our previous as well as in the present study.
Signs of local immunoregulation were, however, noted in the islets themselves. Cytokine analysis performed on the pancreas of normoglycemic mice showed significantly lower levels of IFN␥ and higher levels of IL-4 in protected mice treated with the combination therapy. It has been demonstrated that IFN␥ is the main cytokine whose gene expression is found to correlate with islet ␤-cell destructive insulitis (36). Also the levels of IL-4 mRNA, a cytokine that appears to be protective against diabetes in NOD mice, were elevated locally in the islets of combination-treated mice (34, 40) . These data combined suggest a local immune shift induced by the combination treatment. Note that we did not find a clear effect on IL-12, the key cytokine in immune balance, probably because the analysis was performed only at a later age (200 days).
Finally, all treatments were well tolerated. Mice treated with MC1288 alone had a bone calcium content comparable to that in control mice, whereas those treated with CyA had a significantly lower bone calcium content, confirming the findings in rats treated with CyA (41). The combination therapy, surprisingly, resulted in even lower bone turnover and higher calcium content of bone. These data together with observations made for other analogs of 1,25-(OH) 2 D 3 eliminate the major problem of possible clinical use of the 1,25-(OH) 2 D 3 analogs, namely the hypercalcemia and osteoporosis induced by 1,25-(OH) 2 D 3 itself, and allow the conclusion that treatment with these substances, even over the long term, appears to be safe. Side-effects on systems other than calcium or bone homeostasis have not been described to date.
In conclusion, the approach of combining an acceptable, short induction course of a classical immunosuppressant with nonhypercalcemic analogs of 1,25-(OH) 2 D 3 is promising because it can block the progression from autoimmune ␤-cell attack toward overt clinical disease. Further investigations are necessary and might open new perspectives in the prevention of autoimmune diabetes.
